Novo Nordisk A/S (NOVO-B) - Stock Price & Dividends

Exchange: Copenhagen Exchange • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060534915

Novo Nordisk A/S and its subsidiaries focus on researching, developing, manufacturing, and distributing pharmaceutical products across various geographic regions including Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and beyond.

Operating under two key segments, Diabetes and Obesity Care, and Rare Disease, the company caters to diverse medical needs. The Diabetes and Obesity Care segment specializes in products for conditions like diabetes, obesity, cardiovascular diseases, and other emerging therapy areas. Meanwhile, the Rare Disease segment offers solutions for rare blood disorders, endocrine disorders, and hormone replacement therapy.

Aside from traditional pharmaceuticals, the company also manufactures innovative medical devices like insulin pens, growth hormone pens, and injection needles. Novo Nordisk A/S is pioneering smart solutions for diabetes management, including cutting-edge technologies like smart insulin pens and Dose Check, an application for insulin dose guidance.

Established in 1923 and based in Bagsvaerd, Denmark, Novo Nordisk A/S has a strategic partnership with Aspen Pharmaceuticals to enhance its insulin product portfolio. For more information, you can visit their website at

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Novo Nordisk A/S (NOVO-B) - Stock Price & Dividends

NOVO-B Stock Overview

Market Cap in USD 533,774m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception

NOVO-B Stock Ratings

Fundamental 8.41
Dividend 8.30
Growth 5y 9.47
Rel. Performance vs Sector 3.84
Analysts -
Fair Price Total Ret. 1062.38
Fair Price DCF 566.32

NOVO-B Dividends

Yield 12m 0.85%
Yield on Cost 5y 4.83%
Dividends CAGR 5y 11.67%
Payout Consistency 98.2%

NOVO-B Growth Ratios

Growth 12m 69.58%
Growth Correlation 12m 73%
Growth Correlation 3m 79%
CAGR 5y 41.82%
CAGR / Mean Drawdown 9.55
Sharpe Ratio 12m 2.14
Alpha vs SP500 12m 51.97
Beta vs SP500 5y weekly 0.50
CAPM 6.59%
Average Daily Range 2m 2.08%
Regime Oscillator 56.14
Volatility GJR Garch 1y 26.04%
Price / SMA 50 9.19%
Price / SMA 200 26.95%
Current Volume 1684.9k
Average Volume 20d 2604.2k

External Links for NOVO-B Stock

X (Twitter)Stocktwits
Fund Manager Positions
What is the price of NOVO-B stocks?
As of February 29, 2024, the stock is trading at DKK 834.10 with a total of 1,684,926 shares traded.
Over the past week, the price has changed by +0.40%, over one month by +11.85%, over three months by +21.25% and over the past year by +67.20%.
Why is NOVO-B stock down?
Check with which Index or Commodity NOVO-B has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return NOVO-B Return S&P 500
1 Month 11.85% 3.05%
3 Months 21.25% 11.73%
12 Months 67.20% 29.22%
What is the forecast for NOVO-B stock price target?
According to ValueRays Forecast Model, NOVO-B Novo Nordisk A/S will be worth about 1169.6 in February 2025. The stock is currently trading at 834.10. This means that the stock has a potential upside of +40.22%.
Issuer Forecast Upside
Wallstreet Target Price 793 -4.9%
Analysts Target Price - -
ValueRay Target Price 1169.6 40.2%

The History of Novo Nordisk A/S

Novo Nordisk A/S, a global healthcare company, has its roots firmly planted in Denmark. Born from the merger of two Danish companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium in 1989, its legacy dates back to the early 20th century, focusing on diabetes care. An enduring commitment to innovation and care has guided its journey, evolving from providing insulin to offering a wide range of healthcare solutions.

Core Business

At its core, Novo Nordisk is dedicated to defeating diabetes. Its broad portfolio of insulin products and diabetes care technologies stands testament to this mission. The company leads in diabetic care, investing heavily in research and development to bring forward new treatment options and insulin analogues to improve the quality of life for people with diabetes.

Side Business Ventures

Beyond diabetes care, Novo Nordisk has diversified into other areas of healthcare. This includes haemophilia treatments, growth hormone therapy, and weight management solutions. Each of these sectors represents a strategic expansion, leveraging their extensive knowledge in biopharmaceuticals to address complex health issues, aiming for a holistic approach to healthcare.

Current Market Status

Today, Novo Nordisk A/S (CO:NOVO-B) maintains a strong presence in the global healthcare market. Its continued focus on innovation, along with a growing demand for diabetes care and obesity treatments, positions the company favorably. Despite the inherent challenges in the sector, including regulatory hurdles and market competition, Novo Nordisk's dedication to addressing chronic diseases keeps it at the forefront of the industry. The company's stock reflects its robust financial health and the trust investors place in its mission and strategic direction.